Pyxis Oncology, Inc. announced that the FDA has granted Fast Track Designation for its drug PYX-201, aimed at treating adult patients with recurrent or metastatic head and neck squamous cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback